Publications
Selected publications
- Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. (Journal article - 2023)
- BAP1 loss is associated with higher ASS1 expression in epithelioid mesothelioma: implications for therapeutic stratification. (Journal article - 2023)
- Advances in the clinical management of uveal melanoma (Journal article - 2023)
- The Chick Embryo Xenograft Model for Malignant Pleural Mesothelioma: A Cost and Time Efficient 3Rs Model for Drug Target Evaluation (Journal article - 2022)
- Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial (Journal article - 2022)
- Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma (Journal article - 2022)
- Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs (Journal article - 2022)
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma (Journal article - 2021)
2024
Correction: Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
Zager, J. S., Orloff, M., Ferrucci, P. F., Choi, J., Eschelman, D. J., Glazer, E. S., . . . Ottensmeier, C. H. (2024). Correction: Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.. Annals of surgical oncology, 31(12), 8262-8263. doi:10.1245/s10434-024-15886-6
ASO Visual Abstract: Efficacy and Safety of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter, Phase 3 Study.
Zager, J. S., Orloff, M., Ferrucci, P. F., Choi, J., Eschelman, D. J., Glazer, E. S., . . . Ottensmeier, C. H. (2024). ASO Visual Abstract: Efficacy and Safety of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter, Phase 3 Study.. Annals of surgical oncology, 31(8), 5220-5221. doi:10.1245/s10434-024-15421-7
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
Zager, J. S., Orloff, M., Ferrucci, P. F., Choi, J., Eschelman, D. J., Glazer, E. S., . . . Ottensmeier, C. H. (2024). Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.. Annals of surgical oncology. doi:10.1245/s10434-024-15293-x
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma.
Sacco, J. J., Carvajal, R. D., Butler, M. O., Shoushtari, A. N., Hassel, J. C., Ikeguchi, A., . . . Sato, T. (2024). Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma.. Journal for immunotherapy of cancer, 12(6), e009028. doi:10.1136/jitc-2024-009028
Comparison of clinical outcomes of stable disease with confirmed tumor reduction and RECIST partial response for tebentafusp in metastatic uveal melanoma (mUM).
Ikeguchi, A., Sato, T., Butler, M. O., Carvajal, R. D., Sacco, J. J., Shoushtari, A. N., . . . Hamid, O. (2024). Comparison of clinical outcomes of stable disease with confirmed tumor reduction and RECIST partial response for tebentafusp in metastatic uveal melanoma (mUM).. Journal of Clinical Oncology, 42(16_suppl), 9529. doi:10.1200/jco.2024.42.16_suppl.9529
Efficacy and safety of RP1 combined with nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial.
Wong, M. K. K., Sacco, J. J., Robert, C., Michels, J., Bowles, T. L., In, G. K., . . . Milhem, M. M. (2024). Efficacy and safety of RP1 combined with nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial.. Journal of Clinical Oncology, 42(16_suppl), 9517. doi:10.1200/jco.2024.42.16_suppl.9517
P111 Immuno-pathological characteristics associated with immune-checkpoint inhibitor colitis
Swaminathan, M., Luchian, A., Ressel, L., Burdak-Rothkamm, S., Sacco, J., Pirmohamed, M., & Mark Pritchard, D. (2024). P111 Immuno-pathological characteristics associated with immune-checkpoint inhibitor colitis. In Poster Presentations (pp. A117-A118). BMJ Publishing Group Ltd and British Society of Gastroenterology. doi:10.1136/gutjnl-2024-bsg.193
P140 Investigating circulating miRNAs as diagnostic and prognostic biomarkers of immune checkpoint inhibitor-related colitis
Swaminathan, M., Olsson-Brown, A., Sacco, J., Pirmohamed, M., Parker, J., Yachi, P., & Mark Pritchard, D. (2024). P140 Investigating circulating miRNAs as diagnostic and prognostic biomarkers of immune checkpoint inhibitor-related colitis. In Poster Presentations (pp. A137-A138). BMJ Publishing Group Ltd and British Society of Gastroenterology. doi:10.1136/gutjnl-2024-bsg.222
Safety, efficacy, and biomarker results from an open-label, multicenter, phase 1 study of RP2 alone or combined with nivolumab in a cohort of patients with uveal melanoma.
Sacco, J. J., Harrington, K. J., Olsson-Brown, A., Chan, T. Y., Nenclares, P., Leslie, I., . . . Middleton, M. R. (2024). Safety, efficacy, and biomarker results from an open-label, multicenter, phase 1 study of RP2 alone or combined with nivolumab in a cohort of patients with uveal melanoma.. Journal of Clinical Oncology, 42(16_suppl), 9511. doi:10.1200/jco.2024.42.16_suppl.9511
Use of baseline and serial ctDNA dynamics to predict outcomes in patients treated with first-line tebentafusp, including those who were and were not treated beyond progression.
Sullivan, R. J., Collins, L., Sacco, J. J., Thiyagarajah, P., Nathan, P. D., & Carvajal, R. D. (2024). Use of baseline and serial ctDNA dynamics to predict outcomes in patients treated with first-line tebentafusp, including those who were and were not treated beyond progression.. Journal of Clinical Oncology, 42(16_suppl), 9536. doi:10.1200/jco.2024.42.16_suppl.9536
Oestrogen Receptor Positive Metastatic Eccrine Porocarcinoma: A Case Report and Review of Anti-Oestrogen Therapy in Rare Cancers.
Kalakonda, A. J. M., Mahajan, A., Chow, S., Olsson-Brown, A. C., & Sacco, J. J. (2024). Oestrogen Receptor Positive Metastatic Eccrine Porocarcinoma: A Case Report and Review of Anti-Oestrogen Therapy in Rare Cancers.. Case reports in oncology, 17(1), 497-503. doi:10.1159/000535328
Abstract 2467: Enhanced CD8+T-cell infiltration, PD-L1 expression, and T-cell repertoire expansion in patients with metastatic uveal melanoma responding to treatment with RP2 alone or in combination with nivolumab
Bommareddy, P. K., Kalbasi, A., Harrington, K. J., Olsson-Brown, A., Chan, T. Y., Nenclares, P., . . . Sacco, J. J. (2024). Abstract 2467: Enhanced CD8+T-cell infiltration, PD-L1 expression, and T-cell repertoire expansion in patients with metastatic uveal melanoma responding to treatment with RP2 alone or in combination with nivolumab. Cancer Research, 84(6_Supplement), 2467. doi:10.1158/1538-7445.am2024-2467
A three-arm randomised Phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma
Sacco, J. J., Jackson, R., Corrie, P., Danson, S., Jeffry Evans, T. R., Ochsenreither, S., . . . Nathan, P. (2024). A three-arm randomised Phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma. European Journal of Cancer, 114009. doi:10.1016/j.ejca.2024.114009
A case of immunotherapy-induced thyroiditis.
Pears, G., Mahajan, A., Olsson-Brown, A., & Sacco, J. (2024). A case of immunotherapy-induced thyroiditis.. Exploration of targeted anti-tumor therapy, 5(1), 225-231. doi:10.37349/etat.2024.00214
2023
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
Hassel, J. C., Piperno-Neumann, S., Rutkowski, P., Baurain, J. -F., Schlaak, M., Butler, M. O., . . . Nathan, P. (2023). Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.. The New England journal of medicine, 389(24), 2256-2266. doi:10.1056/nejmoa2304753
Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK.
Ng, K., Metcalf, R., Sacco, J., Kong, A., Wheeler, G., Forsyth, S., . . . Forster, M. (2023). Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK.. BMJ open, 13(11), e070391. doi:10.1136/bmjopen-2022-070391
Initial efficacy and safety of RP1 + nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study.
Chmielowski, B., Milhem, M. M., Sacco, J. J., Bowles, T. L., Tsai, K. K., In, G. K., . . . Middleton, M. R. (2023). Initial efficacy and safety of RP1 + nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study.. Journal of Clinical Oncology, 41(16_suppl), 9509. doi:10.1200/jco.2023.41.16_suppl.9509
Preliminary safety and efficacy results from an open-label, multicenter, phase 1 study of RP2 as a single agent and in combination with nivolumab in a cohort of patients with uveal melanoma.
Sacco, J. J., Harrington, K. J., Olsson-Brown, A., Chan, T. Y., Nenclares, P., Leslie, I., . . . Middleton, M. R. (2023). Preliminary safety and efficacy results from an open-label, multicenter, phase 1 study of RP2 as a single agent and in combination with nivolumab in a cohort of patients with uveal melanoma.. Journal of Clinical Oncology, 41(16_suppl), 9527. doi:10.1200/jco.2023.41.16_suppl.9527
Sensitivity and Specificity of Different Prognostic Systems in Guiding Surveillance for Metastases in Uveal Melanoma
Robinson, H., Eleuteri, A., Sacco, J. J., Hussain, R., Heimann, H., Taktak, A. F. G., . . . Coupland, S. E. (2023). Sensitivity and Specificity of Different Prognostic Systems in Guiding Surveillance for Metastases in Uveal Melanoma. CANCERS, 15(9). doi:10.3390/cancers15092610
BAP1 loss is associated with higher ASS1 expression in epithelioid mesothelioma: implications for therapeutic stratification.
Barnett, S. E., Kenyani, J., Tripari, M., Butt, Z., Grosman, R., Querques, F., . . . Coulson, J. M. (n.d.). BAP1 loss is associated with higher ASS1 expression in epithelioid mesothelioma: implications for therapeutic stratification.. Molecular Cancer Research. doi:10.1158/1541-7786.mcr-22-0635
Total serum <i>N-</i>glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma
Visconti, A., Rossi, N., Deris, H., Lee, K. A., Hanic, M., Trbojevic-Akmacic, I., . . . Falchi, M. (2023). Total serum <i>N-</i>glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma. BMC CANCER, 23(1). doi:10.1186/s12885-023-10511-3
Advances in the clinical management of uveal melanoma
Carvajal, R. D., Sacco, J. J., Jager, M. J., Eschelman, D. J., Olofsson Bagge, R., Harbour, J. W., . . . Piperno-Neumann, S. (2023). Advances in the clinical management of uveal melanoma. NATURE REVIEWS CLINICAL ONCOLOGY, 20(2), 99-115. doi:10.1038/s41571-022-00714-1
Initial efficacy and safety of RP1+nivolumab in patients with anti-PD-1-failed melanoma from the ongoing phase 1/2 IGNYTE study.
Chmielowski, B., Milhem, M. M., Sacco, J. J., Bowles, T. L., Tsai, K. K., In, G. K., . . . Middleton, M. R. (2023). Initial efficacy and safety of RP1+nivolumab in patients with anti-PD-1-failed melanoma from the ongoing phase 1/2 IGNYTE study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 41. Retrieved from https://www.webofscience.com/
Preliminary safety and efficacy results from an open-label, multicenter, phase 1 study of RP2 as a single agent and in combination with nivolumab in a cohort of patients with uveal melanoma.
Sacco, J. J., Harrington, K. J., Olsson-Brown, A., Chan, T. Y., Nenclares, P., Leslie, I., . . . Middleton, M. R. (2023). Preliminary safety and efficacy results from an open-label, multicenter, phase 1 study of RP2 as a single agent and in combination with nivolumab in a cohort of patients with uveal melanoma.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 41. Retrieved from https://www.webofscience.com/
Safety, Efficacy, and Biomarker Assessment of RP1 in Combination With Nivolumab in Patients with Advanced Skin Cancers
Beasley, G. M., VanderWalde, A. M., Bowles, T. L., Sacco, J. J., Niu, J., Tsai, K. K., . . . Milhem, M. M. (2023). Safety, Efficacy, and Biomarker Assessment of RP1 in Combination With Nivolumab in Patients with Advanced Skin Cancers. In ANNALS OF SURGICAL ONCOLOGY Vol. 30 (pp. S9-S10). Retrieved from https://www.webofscience.com/
2022
The Chick Embryo Xenograft Model for Malignant Pleural Mesothelioma: A Cost and Time Efficient 3Rs Model for Drug Target Evaluation
Barnett, S. E., Herrmann, A., Shaw, L., Gash, E. N., Poptani, H., Sacco, J. J., & Coulson, J. M. (2022). The Chick Embryo Xenograft Model for Malignant Pleural Mesothelioma: A Cost and Time Efficient 3Rs Model for Drug Target Evaluation. CANCERS, 14(23). doi:10.3390/cancers14235836
610 Immune biomarker analysis of RP1 in combination with nivolumab in patients with advanced solid tumors
Harrington, K., Nenclares, P., Leslie, I., VanderWalde, A., Bowles, T., Sacco, J., . . . Milhem, M. (2022). 610 Immune biomarker analysis of RP1 in combination with nivolumab in patients with advanced solid tumors. In Regular and Young Investigator Award Abstracts (pp. A642). BMJ Publishing Group Ltd. doi:10.1136/jitc-2022-sitc2022.0610
611 Biodistribution and shedding analysis following treatment with RP1 oncolytic immunotherapy in the skin cancer patients from the IGNYTE clinical trial
Milhem, M., VanderWalde, A., Bowles, T., Sacco, J., Olsson-Brown, A., Niu, J., . . . Harrington, K. (2022). 611 Biodistribution and shedding analysis following treatment with RP1 oncolytic immunotherapy in the skin cancer patients from the IGNYTE clinical trial. In Regular and Young Investigator Award Abstracts (pp. A643). BMJ Publishing Group Ltd. doi:10.1136/jitc-2022-sitc2022.0611
Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial
Carvajal, R. D., Butler, M. O., Shoushtari, A. N., Hassel, J. C., Ikeguchi, A., Hernandez-Aya, L., . . . Sato, T. (n.d.). Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. Nature Medicine. doi:10.1038/s41591-022-02015-7
The Chick Embryo Xenograft Model for Malignant Pleural Mesothelioma: A Cost and Time Efficient 3Rs Model for Target and Compound Evaluation
An open-label, multicenter, phase I study of RP2 as a single agent and in combination with nivolumab in patients with solid tumors: Safety, efficacy, and biomarker results
Harrington, K. J., Sacco, J. J., Olsson-Brown, A., Chan, T., Nenclares, P., Leslie, I., . . . Middleton, M. R. (2022). An open-label, multicenter, phase I study of RP2 as a single agent and in combination with nivolumab in patients with solid tumors: Safety, efficacy, and biomarker results. In ANNALS OF ONCOLOGY Vol. 33 (pp. S926-S927). doi:10.1016/j.annonc.2022.07.953
Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma
Rossi, N., Lee, K. A., Bermudez, M. V., Visconti, A., Thomas, A. M., Bolte, L. A., . . . Falchi, M. (2022). Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma. EBIOMEDICINE, 83. doi:10.1016/j.ebiom.2022.104235
Abstract CT155: Clinical biomarker studies with an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors indicates potent immune activation
Harrington, K. J., Bommareddy, P. K., Middleton, M. R., Sacco, J. J., Olsson-Brown, A., Chan, T. Y., . . . Coffin, R. S. (2022). Abstract CT155: Clinical biomarker studies with an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors indicates potent immune activation. Cancer Research, 82(12_Supplement), CT155. doi:10.1158/1538-7445.am2022-ct155
Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma
Carvajal, R. D., Nathan, P., Sacco, J. J., Orloff, M., Hernandez-Aya, L. F., Yang, J., . . . Sato, T. (n.d.). Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. Journal of Clinical Oncology. doi:10.1200/jco.21.01805
A phase 1 trial of RP2, a first-in-class, enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody as a single agent and combined with nivolumab in patients with advanced solid tumors.
Harrington, K. J., Sacco, J. J., Olsson-Brown, A. C., Chan, T. Y., Nenclares, P., Leslie, I., . . . Middleton, M. R. (2022). A phase 1 trial of RP2, a first-in-class, enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody as a single agent and combined with nivolumab in patients with advanced solid tumors.. Journal of Clinical Oncology, 40(16_suppl), TPS2704. doi:10.1200/jco.2022.40.16_suppl.tps2704
Updated results from the skin cancer cohorts from an ongoing phase 1/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE).
Milhem, M. M., Vanderwalde, A. M., Bowles, T. L., Sacco, J. J., Niu, J., Tsai, K. K., . . . Middleton, M. R. (2022). Updated results from the skin cancer cohorts from an ongoing phase 1/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE).. Journal of Clinical Oncology, 40(16_suppl), 9553. doi:10.1200/jco.2022.40.16_suppl.9553
Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs
Eschweiler, S., Ramirez-Suastegui, C., Li, Y., King, E., Chudley, L., Thomas, J., . . . Ottensmeier, C. H. (2022). Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs. NATURE, 605(7911), 741-+. doi:10.1038/s41586-022-04685-2
Safety and Efficacy of RP1+Nivolumab in Patients with Non-Melanoma Skin Cancer of the Head and Neck: Results From IGNYTE Phase 1/2 Multi-Cohort Clinical Trial
Niu, J., Milhem, M., Vanderwalde, A. M., Chmielowski, B., Beasley, G., Samson, A., . . . Middleton, M. R. (2022). Safety and Efficacy of RP1+Nivolumab in Patients with Non-Melanoma Skin Cancer of the Head and Neck: Results From IGNYTE Phase 1/2 Multi-Cohort Clinical Trial. In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS Vol. 112 (pp. E8-E9). Retrieved from https://www.webofscience.com/
IGNYTE: A Phase 1/2 Multi-Cohort Clinical Trial of RP1 ± Nivolumab in Patients with Non-Small Cell Lung Cancer and Other Solid Tumors
Emamekhoo, H., Patel, S., Rodriguez, E., Riaz, M. K., Giaccone, G., Furqan, M., . . . Middleton, M. R. (2022). IGNYTE: A Phase 1/2 Multi-Cohort Clinical Trial of RP1 ± Nivolumab in Patients with Non-Small Cell Lung Cancer and Other Solid Tumors. In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS Vol. 112 (pp. E12-E13). Retrieved from https://www.webofscience.com/
Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19
Varnai, C., Palles, C., Arnold, R., Curley, H. M., Purshouse, K., Cheng, V. W. T., . . . Cazier, J. -B. (2022). Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19. JAMA NETWORK OPEN, 5(2). doi:10.1001/jamanetworkopen.2022.0130
A phase 1 trial of RP2, a first-in-class, enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody as a single agent and combined with nivolumab in patients with advanced solid tumors
Harrington, K. J., Sacco, J. J., Olsson-Brown, A. C., Chan, T. Y., Nenclares, P., Leslie, I., . . . Middleton, M. R. (2022). A phase 1 trial of RP2, a first-in-class, enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody as a single agent and combined with nivolumab in patients with advanced solid tumors. In JOURNAL OF CLINICAL ONCOLOGY Vol. 40. Retrieved from https://www.webofscience.com/
Integrative omics approach identifies druggable BAP1-dependencies in Uveal Melanoma
Silva, L., Barnett, S., Kenyani, J., Butt, Z., Aughton, K., Hammond, D., . . . Coulson, J. (2022). Integrative omics approach identifies druggable BAP1-dependencies in Uveal Melanoma. In INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE Vol. 63. Retrieved from https://www.webofscience.com/
Preliminary results from the skin cancer cohorts from an ongoing multi-cohort phase 2 clinical trial of RP1 combined with nivolumab (IGNYTE)
Vanderwalde, A. M., Milhem, M. M., Bowles, T. L., Sacco, J. J., Niu, J., Tsai, K. K., . . . Middleton, M. R. (2022). Preliminary results from the skin cancer cohorts from an ongoing multi-cohort phase 2 clinical trial of RP1 combined with nivolumab (IGNYTE). In JOURNAL OF TRANSLATIONAL MEDICINE Vol. 20. Retrieved from https://www.webofscience.com/
Updated results from the skin cancer cohorts from an ongoing phase 1/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE).
Milhem, M. M., Vanderwalde, A. M., Bowles, T. L., Sacco, J. J., Niu, J., Tsai, K. K., . . . Middleton, M. R. (2022). Updated results from the skin cancer cohorts from an ongoing phase 1/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 40. Retrieved from https://www.webofscience.com/
2021
506 IGNYTE: an open-label, multicenter, phase 1/2 (Ph 1/2) clinical trial of RP1 ± nivolumab in patients with advanced solid tumors
Middleton, M., Milhem, M., Aroldi, F., Sacco, J., VanderWalde, A., Baum, S., . . . Harrington, K. (2021). 506 IGNYTE: an open-label, multicenter, phase 1/2 (Ph 1/2) clinical trial of RP1 ± nivolumab in patients with advanced solid tumors. Regular and Young Investigator Award Abstracts, A538. doi:10.1136/jitc-2021-sitc2021.506
507 A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors
Middleton, M., Sacco, J., Harrington, K., Olsson-Brown, A., Chan, T., Nenclares, P., . . . Coffin, R. (2021). 507 A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors. Regular and Young Investigator Award Abstracts, A539. doi:10.1136/jitc-2021-sitc2021.507
Adjuvant management of locally advanced oral squamous cell carcinoma – real world challenges and opportunities
Brooker, R. C., Hobkirk, A., Cashman, H., Sato, T., Broderick, D., Wong, H., . . . Schache, A. G. (n.d.). Adjuvant management of locally advanced oral squamous cell carcinoma – real world challenges and opportunities. British Journal of Oral and Maxillofacial Surgery. doi:10.1016/j.bjoms.2020.08.034
NICO Phase II clinical trial - focus on an emerging immunotherapy strategy for the adjuvant treatment of locally-advanced oral cancers
Brooker, R. C., Schache, A. G., & Sacco, J. J. (2021). NICO Phase II clinical trial - focus on an emerging immunotherapy strategy for the adjuvant treatment of locally-advanced oral cancers. BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 59(8), 959-962. doi:10.1016/j.bjoms.2020.08.059
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Nathan, P., Hassel, J. C., Rutkowski, P., Baurain, J. -F., Butler, M. O., Schlaak, M., . . . Piperno-Neumann, S. (2021). Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. NEW ENGLAND JOURNAL OF MEDICINE, 385(13), 1196-1206. doi:10.1056/NEJMoa2103485
An open-label, multicenter, phase I/II clinical trial of RP1 as a single agent and in combination with nivolumab in patients with solid tumors [IGNYTE]
Aroldi, F., Middleton, M. R., Sacco, J. J., Milhem, M. M., Curti, B. D., VanderWalde, A. M., . . . Harrington, K. J. (2021). An open-label, multicenter, phase I/II clinical trial of RP1 as a single agent and in combination with nivolumab in patients with solid tumors [IGNYTE]. In ANNALS OF ONCOLOGY Vol. 32 (pp. S903-S904). doi:10.1016/j.annonc.2021.08.1478
SAVER: sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasia-a phase II randomised control trial study protocol
McCarthy, C., Sacco, J., Fedele, S., Ho, M., Porter, S., Liloglou, T., . . . Shaw, R. (2021). SAVER: sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasia-a phase II randomised control trial study protocol. TRIALS, 22(1). doi:10.1186/s13063-021-05373-8
Abstract LB180: Clinical biomarker studies with two fusion-enhanced versions of oncolytic HSV (RP1 and RP2) alone and in combination with nivolumab in cancer patients indicate potent immune activation
Harrington, K. J., Aroldi, F., Sacco, J. J., Milhem, M. M., Curti, B. D., Vanderwalde, A. M., . . . Middleton, M. R. (2021). Abstract LB180: Clinical biomarker studies with two fusion-enhanced versions of oncolytic HSV (RP1 and RP2) alone and in combination with nivolumab in cancer patients indicate potent immune activation. Cancer Research, 81(13_Supplement), LB180. doi:10.1158/1538-7445.am2021-lb180
Characterization of liver function tests (LFTs) following tebentafusp (tebe) in previously treated (2L+) metastatic uveal melanoma (mUM) patients (pts).
Sato, T., Carvajal, R. D., Sacco, J. J., Shoushtari, A. N., Hassel, J. C., Ikeguchi, A., . . . Butler, M. O. (2021). Characterization of liver function tests (LFTs) following tebentafusp (tebe) in previously treated (2L+) metastatic uveal melanoma (mUM) patients (pts).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 39. doi:10.1200/JCO.2021.39.15_suppl.e21513
Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles
Ye, W., Olsson-Brown, A., Watson, R. A., Cheung, V. T. F., Morgan, R. D., Nassiri, I., . . . Fairfax, B. P. (2021). Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles. BRITISH JOURNAL OF CANCER, 124(10), 1661-1669. doi:10.1038/s41416-021-01310-3
Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma
Malvehy, J., Samoylenko, I., Schadendorf, D., Gutzmer, R., Grob, J. -J., Sacco, J. J., . . . Gogas, H. (2021). Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 9(3). doi:10.1136/jitc-2020-001621
Cost-utility analysis of a decade of liver screening for metastases using the Liverpool Uveal Melanoma Prognosticator Online (LUMPO)
Eleuteri, A., Rola, A. C., Kalirai, H., Hussain, R., Sacco, J., Damato, B. E., . . . Taktak, A. F. G. (2021). Cost-utility analysis of a decade of liver screening for metastases using the Liverpool Uveal Melanoma Prognosticator Online (LUMPO). COMPUTERS IN BIOLOGY AND MEDICINE, 130. doi:10.1016/j.compbiomed.2021.104221
CHECKPOINT INHIBITOR COLITIS: INSIGHTS FROM BENCH AND BEDSIDE
Gupta, T., Antanaviciute, A., Aulicino, A., Cheung, V., Olsson-Brown, A., Geros, A., . . . Simmons, A. (2021). CHECKPOINT INHIBITOR COLITIS: INSIGHTS FROM BENCH AND BEDSIDE. In GUT Vol. 70 (pp. A195). doi:10.1136/gutjnl-2020-bsgcampus.372
Targeting Oncogenic Gaq Signalling with Focal Adhesion Kinase Inhibitors in Three-Dimensional Models of Uveal Melanoma
Aughton, K., Sacco, J., Devlin, M., Lambert, J., Coupland, S. E., & Kalirai, H. (2021). Targeting Oncogenic Gaq Signalling with Focal Adhesion Kinase Inhibitors in Three-Dimensional Models of Uveal Melanoma. In JOURNAL OF PATHOLOGY Vol. 255 (pp. S54). Retrieved from https://www.webofscience.com/
2020
AN OPEN-LABEL, MULTICENTER, PHASE 1/2 CLINICAL TRIAL OF RP1, AN ENHANCED POTENCY ONCOLYTIC HSV, COMBINED WITH NIVOLUMAB: UPDATED RESULTS FROM THE SKIN CANCER COHORTS
Middleton, M., Aroldi, F., Sacco, J., Milhem, M., Curti, B., VanderWalde, A., . . . Harrington, K. (2020). AN OPEN-LABEL, MULTICENTER, PHASE 1/2 CLINICAL TRIAL OF RP1, AN ENHANCED POTENCY ONCOLYTIC HSV, COMBINED WITH NIVOLUMAB: UPDATED RESULTS FROM THE SKIN CANCER COHORTS. In JOURNAL FOR IMMUNOTHERAPY OF CANCER Vol. 8 (pp. A257). doi:10.1136/jitc-2020-SITC2020.0422
INITIAL RESULTS OF A PHASE 1 TRIAL OF RP2, A FIRST IN CLASS, ENHANCED POTENCY, ANTI-CTLA-4 ANTIBODY EXPRESSING, ONCOLYTIC HSV AS SINGLE AGENT AND COMBINED WITH NIVOLUMAB IN PATIENTS WITH SOLID TUMORS
Aroldi, F., Sacco, J., Harrington, K., Olsson-Brown, A., Nanclares, P., Menezes, L., . . . Middleton, M. (2020). INITIAL RESULTS OF A PHASE 1 TRIAL OF RP2, A FIRST IN CLASS, ENHANCED POTENCY, ANTI-CTLA-4 ANTIBODY EXPRESSING, ONCOLYTIC HSV AS SINGLE AGENT AND COMBINED WITH NIVOLUMAB IN PATIENTS WITH SOLID TUMORS. In JOURNAL FOR IMMUNOTHERAPY OF CANCER Vol. 8 (pp. A256-A257). doi:10.1136/jitc-2020-SITC2020.0421
EACH: A phase II study evaluating the safety and anti-tumour activity of avelumab and cetuximab in recurrent/metastatic squamous cell carcinomas
Forster, M., Metcalf, R., Sacco, J., Kong, A., Wheeler, G., Forsyth, S., . . . White, L. (2020). EACH: A phase II study evaluating the safety and anti-tumour activity of avelumab and cetuximab in recurrent/metastatic squamous cell carcinomas. In ANNALS OF ONCOLOGY Vol. 31 (pp. S665). doi:10.1016/j.annonc.2020.08.1037
Vitiligo and other clinical melanocyte-related adverse events following tebentafusp (IMCgp100) exposure in patients with uveal melanoma
Orloff, M., Sacco, J. J., Nathan, P., Holland, C., Cohen, C., Harper, J., . . . Carvajal, R. D. (2020). Vitiligo and other clinical melanocyte-related adverse events following tebentafusp (IMCgp100) exposure in patients with uveal melanoma. In CANCER RESEARCH Vol. 80. doi:10.1158/1538-7445.AM2020-3295
Looking a Gift Horse in the Mouth: Observations on NHS England's Interim Guidance on Pembrolizumab in Head and Neck Squamous Cell Cancer
Harrington, K. J., Bhide, S. A., Forster, M. D., Good, J. S., Gunn, L., Kong, A., . . . Wong, K. H. (2020). Looking a Gift Horse in the Mouth: Observations on NHS England's Interim Guidance on Pembrolizumab in Head and Neck Squamous Cell Cancer. Clinical Oncology, 32(8), 490-492. doi:10.1016/j.clon.2020.05.016
Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?
Cheung, V. T. F., Gupta, T., Olsson-Brown, A., Subramanian, S., Sasson, S. C., Heseltine, J., . . . Brain, O. (2020). Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?. BRITISH JOURNAL OF CANCER, 123(2), 207-215. doi:10.1038/s41416-020-0882-y
Checkpoint-blocker induced autoimmunity is associated with pretreatment T cell expression profiles and favourable outcome in melanoma
An open-label, single-arm, phase II clinical trial of RP1, an enhanced potency oncolytic herpes virus, combined with nivolumab in four solid tumor types: Initial results from the skin cancer cohorts.
Middleton, M. R., Aroldi, F., Sacco, J., Milhem, M. M., Curti, B. D., Vanderwalde, A. M., . . . Harrington, K. (2020). An open-label, single-arm, phase II clinical trial of RP1, an enhanced potency oncolytic herpes virus, combined with nivolumab in four solid tumor types: Initial results from the skin cancer cohorts.. Journal of Clinical Oncology, 38(15_suppl), e22050. doi:10.1200/jco.2020.38.15_suppl.e22050
Immune checkpoint inhibitor-related colitis assessment and prognosis: can inflammatory bowel disease scoring point the way?
Cheung, V. T. F., Gupta, T., Olsson-Brown, A., Subramanian, S., Sasson, S. C., Heseltine, J., . . . Brain, O. (2020). Immune checkpoint inhibitor-related colitis assessment and prognosis: can inflammatory bowel disease scoring point the way?. In JOURNAL OF CROHNS & COLITIS Vol. 14 (pp. S286-S288). Retrieved from http://gateway.webofknowledge.com/
Su1185 IMMUNE CHECKPOINT INHIBITOR-RELATED COLITIS ASSESSMENT AND PROGNOSIS: CAN UCEIS, MAYO AND NANCY INDEX SCORING POINT THE WAY?
Cheung, V. T., Gupta, T., Olsson-Brown, A. C., Subramanian, S., Sasson, S. C., Heseltine, J., . . . Brain, O. (2020). Su1185 IMMUNE CHECKPOINT INHIBITOR-RELATED COLITIS ASSESSMENT AND PROGNOSIS: CAN UCEIS, MAYO AND NANCY INDEX SCORING POINT THE WAY?. Gastroenterology, 158(6). doi:10.1016/s0016-5085(20)32033-3
Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development.
Figueiredo, C. R., Kalirai, H., Sacco, J. J., Azevedo, R. A., Duckworth, A., Slupsky, J. R., . . . Coupland, S. E. (2020). Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development.. The Journal of Pathology, 250(4), 420-439. doi:10.1002/path.5384
Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the WISTERIA trial protocol
Kong, A., Good, J., Kirkham, A., Savage, J., Mant, R., Llewellyn, L., . . . Mehanna, H. (2020). Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the WISTERIA trial protocol. BMJ OPEN, 10(3). doi:10.1136/bmjopen-2019-033009
P272 Immune checkpoint inhibitor-related colitis assessment and prognosis: can inflammatory bowel disease scoring point the way?
Cheung, V. T. F., Gupta, T., Olsson-Brown, A., Subramanian, S., Sasson, S. C., Heseltine, J., . . . Brain, O. (2020). P272 Immune checkpoint inhibitor-related colitis assessment and prognosis: can inflammatory bowel disease scoring point the way?. Journal of Crohn's and Colitis, 14(Supplement_1), S286-S288. doi:10.1093/ecco-jcc/jjz203.401
A Phase 1 Trial of RP1: A New Oncolytic Virus Alone and in Combination with Nivolumab
Middleton, M., Sacco, J., Merchan, J., Thomassen, A., Curti, B., VanderWalde, A., . . . Harrington, K. (2020). A Phase 1 Trial of RP1: A New Oncolytic Virus Alone and in Combination with Nivolumab. In ANNALS OF SURGICAL ONCOLOGY Vol. 27 (pp. S132). Retrieved from https://www.webofscience.com/
IMMUNE CHECKPOINT INHIBITOR-RELATED COLITIS ASSESSMENT AND PROGNOSIS: CAN UCEIS, MAYO AND NANCY INDEX SCORING POINT THE WAY?
Cheung, V. T., Gupta, T., Olsson-Brown, A. C., Subramanian, S., Sasson, S. C., Heseltine, J., . . . Brain, O. (2020). IMMUNE CHECKPOINT INHIBITOR-RELATED COLITIS ASSESSMENT AND PROGNOSIS: CAN UCEIS, MAYO AND NANCY INDEX SCORING POINT THE WAY?. In GASTROENTEROLOGY Vol. 158 (pp. S535-S536). Retrieved from https://www.webofscience.com/
Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction
Olsson-Brown, A., Lord, R., Sacco, J., Wagg, J., Coles, M., & Pirmohamed, M. (2020). Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction. ENDOCRINE CONNECTIONS, 9(4), 318-325. doi:10.1530/EC-19-0473
2019
Exploring the potential of BH3 mimetic therapy in squamous cell carcinoma of the head and neck
Carter, R. J., Milani, M., Butterworth, M., Alotibi, A., Harper, N., Yedida, G., . . . Varadarajan, S. (2019). Exploring the potential of BH3 mimetic therapy in squamous cell carcinoma of the head and neck. Cell Death and Disease, 10(12). doi:10.1038/s41419-019-2150-8
Implementation of a dedicated immuno-oncology toxicity service reduces the acute impact of immune-related adverse events
Olsson-Brown, A. C., Guinan, T., McKay, M., Thurston, K., Chow, S., Lord, R., & Sacco, J. J. (2019). Implementation of a dedicated immuno-oncology toxicity service reduces the acute impact of immune-related adverse events. Annals of Oncology, 30, v530-v531. doi:10.1093/annonc/mdz253.130
SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)
Nathan, P., Needham, A., Corrie, P. G., Danson, S., Evans, J., Ochsenreither, S., . . . Sacco, J. J. (2019). SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM). Annals of Oncology, 30, v908-v910. doi:10.1093/annonc/mdz394.070
Integration of Checkpoint Inhibitors into the Management of Locally Advanced Head and Neck Cancer - Future Perspectives
Brooker, R. C., Sacco, J. J., & Schache, A. G. (2019). Integration of Checkpoint Inhibitors into the Management of Locally Advanced Head and Neck Cancer - Future Perspectives. Clinical Oncology, 31(7), 424-431. doi:10.1016/j.clon.2019.04.011
An open label, multicenter, phase I/II study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors.
Middleton, M. R., Sacco, J. J., Merchan, J. R., Curti, B. D., Vanderwalde, A. M., Olsson-Brown, A. C., . . . Harrington, K. J. (2019). An open label, multicenter, phase I/II study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37. doi:10.1200/JCO.2019.37.15_suppl.TPS2671
Conjunctival melanoma copy number alterations and correlation with mutation status, tumor features and clinical outcome.
Kenawy, N., Kalirai, H., Sacco, J. J., Lake, S. L., Heegaard, S., Larsen, A. -C., . . . Coupland, S. E. (2019). Conjunctival melanoma copy number alterations and correlation with mutation status, tumor features and clinical outcome.. Pigment cell & melanoma research, 32(4), 564-575. doi:10.1111/pcmr.12767
CD8+Tcell integrin α4β7expression: a potential predictor of severity and steroid sensitivity in checkpoint inhibitor induced colitis
Olsson-Brown, A., Sacco, J., Olsson-Brown, A., Olsson-Brown, A., Cachinho, S., Jolly, C., . . . Pirmohamed, M. (2019). CD8+Tcell integrin α4β7expression: a potential predictor of severity and steroid sensitivity in checkpoint inhibitor induced colitis. In JOURNAL FOR IMMUNOTHERAPY OF CANCER Vol. 7. Retrieved from https://www.webofscience.com/
Implementation of a dedicated immuno-oncology toxicity service reduces the acute impact of immune-related adverse events
Olsson-Brown, A. C., Guinan, T., Mckay, M., Thurston, K., Chow, S., Lord, R., & Sacco, J. J. (2019). Implementation of a dedicated immuno-oncology toxicity service reduces the acute impact of immune-related adverse events. In ANNALS OF ONCOLOGY Vol. 30. Retrieved from https://www.webofscience.com/
Initial results of the phase 1 portion of an ongoing phase 1/2 study of RP1 as a single agent and in combination with nivolumab in patients with solid tumors
Middleton, M., Sacco, J., Merchan, J., Thomassen, A., Curti, B., VanderWalde, A., . . . Harrington, K. (2019). Initial results of the phase 1 portion of an ongoing phase 1/2 study of RP1 as a single agent and in combination with nivolumab in patients with solid tumors. In JOURNAL FOR IMMUNOTHERAPY OF CANCER Vol. 7. Retrieved from https://www.webofscience.com/
SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)
Nathan, P., Needham, A., Corrie, P. G., Danson, S., Evans, J., Ochsenreither, S., . . . Sacco, J. J. (2019). SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM). In ANNALS OF ONCOLOGY Vol. 30. Retrieved from https://www.webofscience.com/
Using Mass-Cytometry approach for the characterisation of the microenvironment of primary uveal melanoma
De Figueiredo, C. R., Kalirai, H., Sacco, J., Coulson, J., & Coupland, S. E. (2019). Using Mass-Cytometry approach for the characterisation of the microenvironment of primary uveal melanoma. In INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE Vol. 60. Retrieved from https://www.webofscience.com/
2018
The unexpected challenges of immunotherapy
Olsson-Brown, A. C., Guinan, T. J., McKay, M., Chow, S., Lord, R., Pirmohamed, M., & Sacco, J. J. (2018). The unexpected challenges of immunotherapy. Annals of Oncology, 29, x20. doi:10.1093/annonc/mdy486.010
Altered Nuclear Expression of the Deubiquitylase BAP1 Cannot be Used as a Prognostic Marker for Canine Melanoma
Jama, N., Farquhar, N., Butt, Z., Coupland, S. E., Sacco, J. J., Scase, T., . . . Killick, D. R. (2018). Altered Nuclear Expression of the Deubiquitylase BAP1 Cannot be Used as a Prognostic Marker for Canine Melanoma. Journal of Comparative Pathology, 162, 50-58. doi:10.1016/j.jcpa.2018.06.007
Recent breakthroughs in metastatic uveal melanoma: a cause for optimism?
Sacco, J. J., Kalirai, H., Kenyani, J., Figueiredo, C. R., Coulson, J. M., & Coupland, S. E. (2018). Recent breakthroughs in metastatic uveal melanoma: a cause for optimism?. FUTURE ONCOLOGY, 14(14), 1335-1338. doi:10.2217/fon-2018-0116
A randomised, double-blind, placebo-controlled phase IIa trial of AMG319 given orally as neoadjuvant therapy in patients with human papillomavirus (HPV) positive and negative head and neck squamous cell carcinoma (HNSCC).
Ottensmeier, C. H. H., Jones, T., Sacco, J. J., McCaul, J. A., Brennan, P., Paterson, C., . . . King, E. (2018). A randomised, double-blind, placebo-controlled phase IIa trial of AMG319 given orally as neoadjuvant therapy in patients with human papillomavirus (HPV) positive and negative head and neck squamous cell carcinoma (HNSCC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36. doi:10.1200/JCO.2018.36.15_suppl.6068
The deubiquitylase USP15 regulates topoisomerase II alpha to maintain genome integrity
Fielding, A. B., Concannon, M., Darling, S., Rusilowicz, E., Sacco, J., Prior, I. A., . . . Coulson, J. M. (2018). The deubiquitylase USP15 regulates topoisomerase II alpha to maintain genome integrity. Oncogene, 37(17), 2326-2342. doi:10.1038/s41388-017-0092-0
Kinome‐wide transcriptional profiling of uveal melanoma reveals new vulnerabilities to targeted therapeutics
Bailey, F. P., Clarke, K., Kalirai, H., Kenyani, J., Shahidipour, H., Falciani, F., . . . Eyers, P. A. (2018). Kinome‐wide transcriptional profiling of uveal melanoma reveals new vulnerabilities to targeted therapeutics. Pigment Cell and Melanoma Research, 31(2), 253-266. doi:10.1111/pcmr.12650
Two distinct clinical trajectories of inflammatory thyroiditis evoked by checkpoint blockade in malignant melanoma.
Olsson-Brown, A. C., Lord, R., Sacco, J. J., Coles, M. C., Wagg, J., & Pirmohamed, M. (2018). Two distinct clinical trajectories of inflammatory thyroiditis evoked by checkpoint blockade in malignant melanoma.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36. doi:10.1200/JCO.2018.36.5_suppl.131
Patterns of BAP1 protein expression provide insights into prognostic significance and the biology of uveal melanoma
Farquhar, N., Thornton, S., Coupland, S. E., Coulson, J., Sacco, J. J., Krishna, Y., . . . Kalirai, H. (2018). Patterns of BAP1 protein expression provide insights into prognostic significance and the biology of uveal melanoma. The Journal of Pathology: Clinical Research, 4(1), 26-38. doi:10.1002/cjp2.86
The unexpected challenges of immunotherapy
Olsson-Brown, A. C., Guinan, T. J., Mckay, M., Chow, S., Lord, R., Pirmohamed, M., & Sacco, J. J. (2018). The unexpected challenges of immunotherapy. In ANNALS OF ONCOLOGY Vol. 29 (pp. 20). Retrieved from https://www.webofscience.com/
2017
Checkpoint Inhibitor induced thyroid immune related adverse events: two distinct clinical patterns
Olsson-Brown, A., Lord, R., Sacco, J., Upton, J., Coles, M., & Pirmohamed, M. (2017). Checkpoint Inhibitor induced thyroid immune related adverse events: two distinct clinical patterns. In DRUG SAFETY Vol. 40 (pp. 1034). Retrieved from https://www.webofscience.com/
Modulating the DNA Damage Response to Improve Treatment Response in Cervical Cancer
Cossar, L. H., Schache, A. G., Risk, J. M., Sacco, J. J., Jones, N. J., & Lord, R. (2017). Modulating the DNA Damage Response to Improve Treatment Response in Cervical Cancer. Clinical Oncology, 29(9), 626-634. doi:10.1016/j.clon.2017.03.002
Using QR codes to enable quick access to information in acute cancer care.
Upton, J., Olsson-Brown, A., Marshall, E., & Sacco, J. (2017). Using QR codes to enable quick access to information in acute cancer care.. British journal of nursing (Mark Allen Publishing), 26(10), S4-S12. doi:10.12968/bjon.2017.26.10.s4
Gene expression profiling in bladder cancer identifies potential therapeutic targets
Hussain, S. A., Palmeri, D. H., Syn, W. -K., Sacco, J. J., Greensmith, R. M. D., Elmetwali, T., . . . James, N. D. (2017). Gene expression profiling in bladder cancer identifies potential therapeutic targets. INTERNATIONAL JOURNAL OF ONCOLOGY, 50(4), 1147-1159. doi:10.3892/ijo.2017.3893
Relationship between talimogene laherparepvec and intratumoral CD8+density in patients with unresectable stage IIIB-IVM1c melanoma: Interim efficacy, safety and biomarker results of a Phase 2 study
Malvehy, J., Samoylenko, I., Schadendorf, D., Gutzmer, R., Grob, J. -J., Sacco, J., . . . Gogas, H. (2017). Relationship between talimogene laherparepvec and intratumoral CD8+density in patients with unresectable stage IIIB-IVM1c melanoma: Interim efficacy, safety and biomarker results of a Phase 2 study. In JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY Vol. 31 (pp. 39-40). Retrieved from https://www.webofscience.com/
Safety, efficacy and biology of the gp100 TCR-based bispecific T cell redirector, IMCgp100 in advanced uveal melanoma in two Phase 1 trials
Carvajal, R., Sato, T., Shoushtari, A. N., Sacco, J., Nathan, P., Orloff, M., . . . Middleton, M. R. (2017). Safety, efficacy and biology of the gp100 TCR-based bispecific T cell redirector, IMCgp100 in advanced uveal melanoma in two Phase 1 trials. In JOURNAL FOR IMMUNOTHERAPY OF CANCER Vol. 5. Retrieved from https://www.webofscience.com/
2016
Challenges and Strategies in Precision Medicine for Non-Small-Cell Lung Cancer
Sacco, J. J., Al-Akhrass, H., & Wilson, C. M. (2016). Challenges and Strategies in Precision Medicine for Non-Small-Cell Lung Cancer. CURRENT PHARMACEUTICAL DESIGN, 22(28), 4374-4385. doi:10.2174/1381612822666160603014932
BAP1-deficient mesothelioma: identifying mechanisms for response to HDAC inhibitors and screening for novel drug sensitivities
Butt, Z., Kenyani, J., Sacco, J., & Coulson, J. (2016). BAP1-deficient mesothelioma: identifying mechanisms for response to HDAC inhibitors and screening for novel drug sensitivities. In EUROPEAN JOURNAL OF CANCER Vol. 61 (pp. S180-S181). doi:10.1016/S0959-8049(16)61640-4
Systemic listeriosis following vaccination with the attenuated <i>Listeria monocytogenes</i> therapeutic vaccine, ADXS11-001
Sacco, J. J., Evans, M., Harrington, K. J., Man, S., Powell, N., Shaw, R. J., & Jones, T. M. (2016). Systemic listeriosis following vaccination with the attenuated <i>Listeria monocytogenes</i> therapeutic vaccine, ADXS11-001. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 12(4), 1085-1086. doi:10.1080/21645515.2015.1121338
2015
Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors
Sacco, J., Kenyani, J., Butt, Z., Carter, R., Chew, H. Y., Cheeseman, L. P., . . . Coulson, J. (2015). Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors. Oncotarget, 6(15), 13757-13771. doi:10.18632/oncotarget.3765
Dysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistance
Sacco, J., & Clague, M. (2015). Dysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistance. Translational Lung Cancer Research, 4(3), 242-252. doi:10.3978/j.issn.2218-6751.2015.03.05
2014
The deubiquitylase Ataxin-3 restricts PTEN transcription in lung cancer cells
Sacco, J., Yau, T. Y., Darling, S., Patel, V., Liu, H., Urbe, S., . . . Coulson, J. (2014). The deubiquitylase Ataxin-3 restricts PTEN transcription in lung cancer cells. Oncogene, 33(33), 4265-4272. doi:10.1038/onc.2013.512
2013
Gene expression profiling in bladder cancer to identify potential therapeutic targets.
Hussain, S. A., Palmer, D. H., Syn, W. K., Sacco, J. J., Lloyd, B., Jithesh, P., . . . James, N. D. (2013). Gene expression profiling in bladder cancer to identify potential therapeutic targets.. Journal of Clinical Oncology, 31(15_suppl), 4518. doi:10.1200/jco.2013.31.15_suppl.4518
Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma.
Sacco, J. J., Nathan, P. D., Danson, S., Lorigan, P., Nicholson, S., Ottensmeier, C., . . . Marshall, E. (2013). Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma.. Journal of Clinical Oncology, 31(15_suppl), 9031. doi:10.1200/jco.2013.31.15_suppl.9031
2010
Emerging Roles of Deubiquitinases in Cancer-Associated Pathways
Sacco, J. J., Coulson, J. M., Clague, M. J., & Urbe, S. (2010). Emerging Roles of Deubiquitinases in Cancer-Associated Pathways. IUBMB LIFE, 62(2), 140-157. doi:10.1002/iub.300
The Average Body Surface Area of Adult Cancer Patients in the UK: A Multicentre Retrospective Study
Sacco, J. J., Botten, J., Macbeth, F., Bagust, A., & Clark, P. (2010). The Average Body Surface Area of Adult Cancer Patients in the UK: A Multicentre Retrospective Study. PLOS ONE, 5(1). doi:10.1371/journal.pone.0008933
2008
A neurological phenotype in mice with DNA repair gene <i>Ercc1</i> deficiency
Lawrence, N. J., Sacco, J. J., Brownstein, D. G., Gillingwater, T. H., & Melton, D. W. (2008). A neurological phenotype in mice with DNA repair gene <i>Ercc1</i> deficiency. DNA REPAIR, 7(2), 281-291. doi:10.1016/j.dnarep.2007.10.005